Archive
3 postsFilters: category: ehs Clear
EHS vs. “EMR Syndrome”: Protecting Children Requires Mechanisms and Solutions, Not Ideological Paralysis
RF Safe argues that the established term “electromagnetic hypersensitivity” (EHS) should not be replaced by the newer label “EMR Syndrome,” claiming the rebranding fragments research and weakens advocacy. The piece frames EHS as a continuity-based concept tied to reported symptoms in EMF-rich environments and emphasizes practical mitigation via engineering, architecture, and policy—especially to reduce children’s exposure. It uses “EMR Syndrome” narrowly to describe what it portrays as an ideological, anti-technology pattern that blocks solutions rather than a physiological condition.
Metabolic modulation fits the S4 Timing Fidelity model
RF Safe argues that an acute laboratory finding—reported as increased ad-libitum energy intake after brief 3G handset exposure versus sham—supports its proposed “S4 Timing Fidelity” mechanism for non-thermal RF effects. The post links the behavioral outcome to hypothalamic energy-sensing and autonomic changes via voltage-gated ion channel (VGIC) gating perturbations, and further connects this to mitochondrial/oxidative phosphorylation signaling. It also frames electromagnetic hypersensitivity (EHS) as a sensitivity phenotype and proposes testable predictions involving pulse structure and physiological correlates (e.g., HRV, EEG).
Polarized, coherent fields with embedded extremely low-frequency (ELF) components
RF Safe argues that non-thermal RF-EMF effects on biology may be driven by extremely low-frequency (ELF) components embedded in real-world, modulated wireless signals rather than by the RF carrier alone. The post highlights Panagopoulos’ ion-forced-oscillation (IFO) model as a proposed mechanism in which ELF-related ion motion could perturb voltage-gated ion channel (VGIC) gating and cascade into oxidative stress and immune effects. It cites a mix of supportive and null findings and frames electromagnetic hypersensitivity (EHS) as a threshold/phenotype within the same proposed VGIC–mitochondria–ROS pathway.